Activation of the peripheral endocannabinoid system in human obesity

Diabetes

Volumn 54, Issue 10, 2005, Pages 2838-2843

  Engeli, Stefan ^a   Böhnke, Jana ^a   Feldpausch, Mareike ^a   Gorzelniak, Kerstin ^a   Janke, Jürgen ^a   Bátkai, Sándor ^b   Pacher, Pál ^b   Harvey White, Judy ^b   Luft, Friedrich C ^a   Sharma, Arya M ^c   Jordan, Jens ^a  

^a FRANZ VOLHARD CLINIC   (Germany)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CHOLESTEROL; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCEROL; INSULIN; TRIACYLGLYCEROL;

ADIPOCYTE; ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; AMIDOHYDROLASES; ARACHIDONIC ACIDS; BODY COMPOSITION; BODY MASS INDEX; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION; GLYCERIDES; HUMANS; LINEAR MODELS; MIDDLE AGED; OBESITY; POLYUNSATURATED ALKAMIDES; POSTMENOPAUSE; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; WEIGHT LOSS;

EID: 25844460609     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.10.2838     Document Type: Article

References (37)

1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB: Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867-1872, 2002
2. Janssen I, Katzmarzyk PT, Ross R: Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 162:2074-2079, 2002
3. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Eanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
4. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693, 2004
5. Jamshidi N, Taylor DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154, 2001
6. Williams CM, Kirkham TC: Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 76:241-250, 2002
7. Williams CM, Kirkham TC: Anandamide induces overeating: mediation by central cannabinoid receptors. Psychopharmacology (Berl) 143:315-317, 1999
8. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U: Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289-301, 2003
9. Berry EM, Mechoulam R: Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 95:185-190, 2002
10. Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884, 2003
11. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202, 2002
12. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825, 2001
13. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G: Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 952:232-238, 2002
14. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648, 2004
15. Ravinet TC, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol 284:R345-R353, 2003
16. Cota D, Marsicano G, Tschöp M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431, 2003
17. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914, 2003
18. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305, 2005
19. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397, 2005
20. Black SC: Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5:389-394, 2004
21. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Möhlig M, Pfeiffer AF, Luft FC, Sharma AM: Association between adiponectin and mediators of inflammation in obese women. Diabetes 52:942-947, 2003
22. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45:356-362, 2005
23. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51:1699-1707, 2002
24. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G: Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 100:1393-1398, 2003
25. Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, Finazzi AA, Suris R, Mechoulam R, Di Marzo V: Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod 11:21-28, 2005
26. Maccarrone M, Di Rienzo M, Finazzi-Agro A, Rossi A: Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J Biol Chem 278:13318-13324, 2003
27. Sipe JC, Waalen J, Gerber A, Beutler E: Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes Relat Metab Disord 29:755-759, 2005
28. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404, 1999
29. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110:1996-2002, 2004
30. Pacher P, Batkai S, Kunos G: Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacol 48:1130-1138, 2005
31. Hogestatt ED, Zygmunt PM: Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 66:343-351, 2002
32. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209, 2004
33. Lavon I, Sheinin T, Meilin S, Biton E, Weksler A, Efroni G, Bar-Joseph A, Fink G, Avraham A: A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 64:1334-1341, 2003
34. Klein TW, Newton C, Larsen K, Lu L, Ferions I, Nong L, Friedman H: The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496, 2003
35. Nieri P, Greco R, Adinolfi B, Breschi MC, Martinotti E, Nannetti C, Podesta A: CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. Naunyn Schmiedebergs Arch Pharmacol 368:352-359, 2003
36. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM: Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 92:757-761, 2004
37. Tucci SA, Rogers EK, Korbonits M, Kirkham TC: The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520-523, 2004